



Brunei International Medical Journal

OFFICIAL PUBLICATION OF
THE MINISTRY OF HEALTH
AND
UNIVERSITI BRUNEI DARUSSALAM

Volume 17

10 March 2021 (26 Rejab 1442H)

LIVING WELL WITH KIDNEY DISEASE BY PATIENT AND CARE-PARTNER EMPOWERMENT: KIDNEY HEALTH FOR EVERYONE EVERYWHERE.

Kamyar KALANTAR-ZADEH*¹, Philip Kam-Tao LI*², Ekamol TANTISATTAMO³, Latha KUMARASWAMI⁴, Vassilios LIAKOPOULOS⁵, Siu-Fai LUI⁶, Ifeoma ULASI⁷, Sharon ANDREOLI⁸, Alessandro BALDUCCI⁹, Sophie DUPUIS¹⁰, Tess HARRIS¹¹, Anne HRADSKY¹⁰, Richard KNIGHT¹², Sajay KUMAR⁴, Maggie NG¹³, Alice POIDEVIN¹⁰, Gamal SAADI¹⁴, and Allison TONG¹⁵, for the World Kidney Day Steering Committee#

ABSTRACT

Living with chronic kidney disease is associated with hardships for patients and their care-partners. Empowering patients and their care-partners, including family members or friends involved in their care, may help minimize the burden and consequences of CKD related symptoms to enable life participation. There is a need to broaden the focus on living well with kidney disease and re-engagement in life, including an emphasis on patients being in control. The World Kidney Day Joint Steering Committee has declared 2021 the year of "Living Well with Kidney Disease" to increase education and awareness on the important goal of patient empowerment and life participation. This calls for the development and implementation of validated patient-reported outcome measures to assess and address areas of life participation in routine care. It could be supported by regulatory agencies as a metric for quality care or to support labelling claims for medicines and devices. Funding agencies could establish targeted calls for research that address the priorities of patients. Patients with kidney disease and their care-partners should feel supported to live well through concerted efforts by kidney care communities including during pandemics. In the overall wellness program for kidney disease patients, the need for prevention should be reiterated. Early detection with a prolonged course of wellness despite kidney disease, after effective secondary and tertiary prevention programs, should be promoted. World Kidney Day 2021 continues to call for increased awareness of the importance of preventive measures throughout populations, professionals, and policy makers, applicable to both developed and developing countries.

Keywords: Patient empowerment, care-partner, low-middle-income countries, health policy.

Brunei Int Med J. 2021;17:17-25

ISSN 1560 5876 Print
ISSN 2079 3146 Online

Online version of the journal is available at www.bimjonline.com

Brunei International Medical Journal (BIMJ) Official Publication of The Ministry of Health and Universiti Brunei Darussalam

EDITORIAL BOARD

Editor-in-Chief	Ketan PANDE
Sub-Editors	Vui Heng CHONG William Chee Fui CHONG
Editorial Board Members	Muhd Syafiq ABDULLAH Alice Moi Ling YONG Ahmad Yazid ABDUL WAHAB Jackson Chee Seng TAN Pemasiri Upali TELISINGHE Pengiran Khairol Asmee PENGIRAN SABTU Dayangku Siti Nur Ashikin PENGIRAN TENGAH

INTERNATIONAL EDITORIAL BOARD MEMBERS

Lawrence HO Khok Yu (Singapore)	Chuen Neng LEE (Singapore)
Wilfred PEH (Singapore)	Emily Felicia Jan Ee SHEN (Singapore)
Surinderpal S BIRRING (United Kingdom)	Leslie GOH (United Kingdom)
John YAP (United Kingdom)	Ian BICKLE (United Kingdom)
Nazar LUQMAN (Australia)	Christopher HAYWARD (Australia)
Jose F LAPENA (Philippines)	

Advisor

Wilfred PEH (Singapore)

Past Editors-in-Chief

Nagamuttu RAVINDRANATHAN
Kenneth Yuh Yen KOK
Chong Vui Heng
William Chong Chee Fui

Proof reader

John WOLSTENHOLME (CfBT Brunei Darussalam)

Aim and Scope of Brunei International Medical Journal

The Brunei International Medical Journal (BIMJ) is a six monthly peer reviewed official publication of the Ministry of Health under the auspices of the Clinical Research Unit, Ministry of Health, Brunei Darussalam.

The BIMJ publishes articles ranging from original research papers, review articles, medical practice papers, special reports, audits, case reports, images of interest, education and technical/innovation papers, editorials, commentaries and letters to the Editor. Topics of interest include all subjects that relate to clinical practice and research in all branches of medicine, basic and clinical including topics related to allied health care fields. The BIMJ welcomes manuscripts from contributors, but usually solicits reviews articles and special reports. Proposals for review papers can be sent to the Managing Editor directly. Please refer to the contact information of the Editorial Office.

Instruction to authors

Manuscript submissions

All manuscripts should be sent to the Managing Editor, BIMJ, Ministry of Health, Brunei Darussalam; e-mail: editor-in-chief@bimjonline.com. Subsequent correspondence between the BIMJ and authors will, as far as possible via should be conducted via email quoting the reference number.

Conditions

Submission of an article for consideration for publication implies the transfer of the copyright from the authors to the BIMJ upon acceptance. The final decision of acceptance rests with the Editor-in-Chief. All accepted papers become the permanent property of the BIMJ and may not be published elsewhere without written permission from the BIMJ.

Ethics

Ethical considerations will be taken into account in the assessment of papers that have experimental investigations of human or animal subjects. Authors should state clearly in the Materials and Methods section of the manuscript that institutional review board has approved the project. Those investigators without such review boards should ensure that the principles outlined in the Declaration of Helsinki have been followed.

Manuscript categories

Original articles

These include controlled trials, interventional studies, studies of screening and diagnostic tests, outcome studies, cost-effectiveness analyses, and large-scale epidemiological studies. Manuscript should include the following; introduction, materials and methods, results and conclusion. The objective should be stated clearly in the introduction. The text should not exceed 2500 words and references not more than 30.

Review articles

These are, in general, invited papers, but unsolicited reviews, if of good quality, may be considered. Reviews are systematic critical assessments of

literature and data sources pertaining to clinical topics, emphasising factors such as cause, diagnosis, prognosis, therapy, or prevention. Reviews should be made relevant to our local setting and preferably supported by local data. The text should not exceed 3000 words and references not more than 40.

Special Reports

This section usually consist of invited reports that have significant impact on healthcare practice and usually cover disease outbreaks, management guidelines or policy statement paper.

Audits

Audits of relevant topics generally follow the same format as original article and the text should not exceed 1,500 words and references not more than 20.

Case reports

Case reports should highlight interesting rare cases or provide good learning points. The text should not exceed 1000 words; the number of tables, figures, or both should not be more than two, and references should not be more than 15.

Education section

This section includes papers (i.e. how to interpret ECG or chest radiography) with particular aim of broadening knowledge or serve as revision materials. Papers will usually be invited but well written paper on relevant topics may be accepted. The text should not exceed 1500 words and should include not more than 15 figures illustration and references should not be more than 15.

Images of interest

These are papers presenting unique clinical encounters that are illustrated by photographs, radiographs, or other figures. Image of interest should include a brief description of the case and discussion with educational aspects. Alternatively, a mini quiz can be presented and answers will be posted in a different section of the publication. A maximum of

three relevant references should be included. Only images of high quality (at least 300dpi) will be acceptable.

Technical innovations

This section include papers looking at novel or new techniques that have been developed or introduced to the local setting. The text should not exceed 1000 words and should include not more than 10 figures illustration and references should not be more than 10.

Letters to the Editor

Letters discussing a recent article published in the BIMJ are welcome and should be sent to the Editorial Office by e-mail. The text should not exceed 250 words; have no more than one figure or table, and five references.

Criteria for manuscripts

Manuscripts submitted to the BIMJ should meet the following criteria: the content is original; the writing is clear; the study methods are appropriate; the data are valid; the conclusions are reasonable and supported by the data; the information is important; and the topic has general medical interest. Manuscripts will be accepted only if both their contents and style meet the standards required by the BIMJ.

Authorship information

Designate one corresponding author and provide a complete address, telephone and fax numbers, and e-mail address. The number of authors of each paper should not be more than twelve; a greater number requires justification. Authors may add a publishable footnote explaining order of authorship.

Group authorship

If authorship is attributed to a group (either solely or in addition to one or more individual authors), all members of the group must meet the full criteria and requirements for authorship described in the following paragraphs. One or more authors may take responsibility 'for' a group, in which case the other group members are not authors, but may be listed in an acknowledgement.

Authorship requirement

When the BIMJ accepts a paper for publication, authors will be asked to sign statements on (1) financial disclosure, (2) conflict of interest and (3) copyright transfer. The correspondence author may sign on behalf of co-authors.

Authorship criteria and responsibility

All authors must meet the following criteria: to have participated sufficiently in the work to take public responsibility for the content; to have made substantial contributions to the conception and de-

sign, and the analysis and interpretation of the data (where applicable); to have made substantial contributions to the writing or revision of the manuscript; and to have reviewed the final version of the submitted manuscript and approved it for publication. Authors will be asked to certify that their contribution represents valid work and that neither the manuscript nor one with substantially similar content under their authorship has been published or is being considered for publication elsewhere, except as described in an attachment. If requested, authors shall provide the data on which the manuscript is based for examination by the editors or their assignees.

Financial disclosure or conflict of interest

Any affiliation with or involvement in any organisation or entity with a direct financial interest in the subject matter or materials discussed in the manuscript should be disclosed in an attachment. Any financial or material support should be identified in the manuscript.

Copyright transfer

In consideration of the action of the BIMJ in reviewing and editing a submission, the author/s will transfer, assign, or otherwise convey all copyright ownership to the Clinical Research Unit, RIPAS Hospital, Ministry of Health in the event that such work is published by the BIMJ.

Acknowledgements

Only persons who have made substantial contributions but who do not fulfill the authorship criteria should be acknowledged.

Accepted manuscripts

Authors will be informed of acceptances and accepted manuscripts will be sent for copyediting. During copyediting, there may be some changes made to accommodate the style of journal format. Attempts will be made to ensure that the overall meaning of the texts are not altered. Authors will be informed by email of the estimated time of publication. Authors may be requested to provide raw data, especially those presented in graph such as bar charts or figures so that presentations can be constructed following the format and style of the journal. Proofs will be sent to authors to check for any mistakes made during copyediting. Authors are usually given 72 hours to return the proof. No response will be taken as no further corrections required. Corrections should be kept to a minimum. Otherwise, it may cause delay in publication.

Offprint

Contributors will not be given any offprint of their published articles. Contributors can obtain an electronic reprint from the journal website.

DISCLAIMER

All articles published, including editorials and letters, represent the opinion of the contributors and do not reflect the official view or policy of the Clinical Research Unit, the Ministry of Health or the institutions with which the contributors are affiliated to unless this is clearly stated. The appearance of advertisement does not necessarily constitute endorsement by the Clinical Research Unit or Ministry of Health, Brunei Darussalam. Furthermore, the publisher cannot accept responsibility for the correctness or accuracy of the advertisers' text and/or claim or any opinion expressed.

LIVING WELL WITH KIDNEY DISEASE BY PATIENT AND CARE-PARTNER EMPOWERMENT: KIDNEY HEALTH FOR EVERYONE EVERYWHERE.



Kamyar KALANTAR-ZADEH^{*1}, Philip Kam-Tao LI^{*2}, Ekamol TANTISATTAMO³, Latha KUMARASWAMI⁴, Vassilios LIAKOPOULOS⁵, Siu-Fai LUI⁶, Ifeoma ULASI⁷, Sharon ANDREOLI⁸, Alessandro BALDUCCI⁹, Sophie DUPUIS¹⁰, Tess HARRIS¹¹, Anne HRADSKY¹⁰, Richard KNIGHT¹², Sajay KUMAR⁴, Maggie NG¹³, Alice POIDEVIN¹⁰, Gamal SAADI¹⁴, and Allison TONG¹⁵, for the World Kidney Day Steering Committee#

¹The International Federation of Kidney Foundation – World Kidney Alliance (IFKF-WKA), Division of Nephrology and Hypertension and Kidney Transplantation, University of California Irvine, Orange, California, USA,

²Department of Medicine and Therapeutics, Carol & Richard Yu PD Research Centre, Prince of Wales Hospital, Chinese University of Hong Kong, Hong Kong,

³Division of Nephrology, Hypertension and Kidney Transplantation, Department of Medicine, University of California Irvine School of Medicine, Orange, California, USA,

⁴Tanker Foundation, Chennai, India,

⁵Division of Nephrology and Hypertension, 1st Department of Internal Medicine, AHEPA Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece,

⁶Hong Kong Kidney Foundation and the International Federation of Kidney Foundations – World Kidney Alliance, The Jockey Club School of Public Health and Primary Care, The Chinese University of Hong Kong, Hong Kong, China,

⁷Renal Unit, Department of Medicine, College of Medicine, University of Nigeria, Ituku-Ozalla, Enugu, Nigeria,

⁸James Whitcomb Riley Hospital for Children, Indiana University School of Medicine, Indianapolis, Indiana, USA,

⁹Italian Kidney Foundation, Rome, Italy,

¹⁰World Kidney Day Office, Brussels, Belgium,

¹¹Polycystic Kidney Disease Charity, London, UK,

¹²American Association of Kidney Patients. Tampa, Florida, USA,

¹³Hong Kong Kidney Foundation, Hong Kong, China,

¹⁴Nephrology Unit, Department of Internal Medicine, Faculty of Medicine, Cairo University, Giza, Egypt,

¹⁵Sydney School of Public Health, The University of Sydney, Sydney, New South Wales, Australia.

Members of the World Kidney Day Steering Committee are: Philip Kam Tao Li, Kamyar Kalantar-Zadeh, Sharon Andreoli, Alessandro Balducci, Sophie Dupuis, Latha Kumaraswami, Vassilios Liakopoulos, Siu-Fai Lui, Gamal Saadi, and Ifeoma Ulasi.

Correspondence: Kamyar Kalantar-Zadeh, MD, MPH, PhD, Division of Nephrology and Hypertension and Kidney Transplantation, University of California Irvine School of Medicine, Orange, California, USA

Tel: (714) 456-5142, Fax: (714) 456-6034; Email: kkz@uci.edu

Philip Kam-Tao Li, MD FRCP FACP, Department of Medicine and Therapeutics, Prince of Wales Hospital, Chinese University of Hong Kong, 30-32 Ngan Shing Street, Shatin, New Territories, Hong Kong, China
Email: philipli@cuhk.edu.hk; ORCID: 0000-0001-9879-8388

ABSTRACT

Living with chronic kidney disease is associated with hardships for patients and their care-partners. Empowering patients and their care-partners, including family members or friends involved in their care, may help minimize the burden and consequences of CKD related symptoms to enable life participation. There is a need to broaden the focus on living well with kidney disease and re-engagement in life, including an emphasis on patients being in control. The World Kidney Day Joint Steering Committee has declared 2021 the year of "Living Well with Kidney Disease" to increase education and awareness on the important goal of patient empowerment and life participation. This calls for the development and implementation of validated patient-reported outcome measures to assess and address areas of life participation in routine care. It could be supported by regulatory agencies as a metric for quality care or to support labelling claims for medicines and devices. Funding agencies could establish targeted calls for research that address the priorities of patients. Patients with kidney disease and their care-partners should feel supported to live well through concerted efforts by kidney care communities including during pandemics. In the overall wellness program for kidney disease patients, the need for prevention should be reiterated. Early detection with a prolonged course of wellness despite kidney disease, after effective secondary and tertiary prevention programs, should be promoted. World Kidney Day 2021 continues to call for increased awareness of the importance of preventive measures throughout populations, professionals, and policy makers, applicable to both developed and developing countries.

Keywords: Patient empowerment, care-partner, low-middle-income countries, health policy.

PATIENT PRIORITIES FOR LIVING WELL: A FOCUS ON LIFE PARTICIPATION

Chronic kidney disease (CKD), its associated symptoms, and its treatment, including medications, dietary and fluid restrictions, and kidney replacement therapy can disrupt and constrain daily living, and impair the overall quality of life of patients and their family members. Consequently, this can also impact treatment satisfaction and clinical outcomes.¹ Despite this, the past several decades have seen limited improvement in the quality of life of people with CKD.¹ To advance research, practice, and policy, there is increasing recognition of the need to identify and address patient priorities, values, and goals.¹

Several regional and global kidney health projects have addressed these important questions including the *Standardised Outcomes in Nephrology* (SONG) with more

than 9,000 patients, family members, and health professionals from over 70 countries.² Across all treatment stages, including CKD, dialysis and transplantation, SONG participating children and adults with CKD consistently gave higher priority to symptoms and life impacts than health professionals.^{2, 3} In comparison, health professionals gave higher priority to mortality and hospitalization than patients and family members. The patient-prioritized outcomes are shown in [Figure 1](#). Irrespective of the type of kidney disease or treatment stage, patients want to be able to live well, maintain their role and social functioning, protect some semblance of normality, and have a sense of control over their health and wellbeing.

'Life participation', defined as the ability to do meaningful activities of life including, but not limited to, work, study, family responsibilities, travel, sport, social, and




Figure 1: Conceptual framework of "Living Well with Kidney Disease" based on patient centeredness and empowering patient with focus on effective symptom management and life participation.

recreational activities, was established a critically important outcome across all treatment stages of CKD.^{1, 2} The quotations from patients with kidney disease provided in [Box 1](#) demonstrates how life participation reflects the ability to live well with CKD.⁴ According to the World Health Organization (WHO), participation refers to "involvement in a life situation".⁵ This concept is more specific than the broader construct of quality of life. Life participation places the life priorities and values of those affected by CKD and their family at the center of decision making. The World Kidney Day Steering Committee (WKDSC) calls for the inclusion of life participation, a key focus in the care of patients with CKD, to achieve the ultimate goal of living well with kidney disease. This calls for the development and implementation of validated patient-reported outcome measures, that could be used to assess and address areas of life participation in routine care. Monitoring of life participation could be supported by regulatory agencies as a metric for quality care or to support labelling claims for medicines and

devices. Funding agencies could establish targeted calls for research that address the priorities of patients, including life participation.

PATIENT EMPOWERMENT, PARTNERSHIP AND A PARADIGM SHIFT TOWARDS A STRENGTHS-BASED APPROACH TO CARE

Patients with CKD and their family members including care-partners should be empowered to achieve the health outcomes and life goals that are meaningful and important to them. The WHO defines patient empowerment as "a process through which people gain greater control over decisions or actions affecting their health", which requires patients to understand their role, to have knowledge to be able to engage with clinicians in shared decision-making, skills, and support for self-management.⁶ For patients receiving dialysis, understanding the rationale for a lifestyle change, having access to practical assistance and family support promoted patient empow-

Box 1: Quotations from patients with CKD related to priorities for living well.

"I don't want to think about dying from my disease. I want to be able to live well with my disease." – Patient with CKD
"Life participation is most important because without it, you can't do anything." – Child with CKD
"Maybe it's as simple as asking patients whether, how well they are able to participate in the life that they want to lead because it's going to be different for different people" – Kidney transplant recipient
"Everyone has to face death, what I would like to have is a good quality of life rather than to face death." – Kidney transplant recipient
"So, it doesn't actually really matter what the numbers say, and some of my numbers should have suggested that I should be feeling a lot worse than what I actually was, it's about how much I feel I can do and participate in my life and feel normal." – Patient with CKD
"I'm still living. I get out of bed, and I'm still living and still breathing. As long as I can do that, I'm going to carry on and be positive because life is short." Patient with CKD
"I put life participation because I know that looking from the outside, I know [his kidney disease] stops [him] from thinking bigger. . . Although that's really big, there's this life that has to happen at the same time." – Family member
"Amazed at comments from professional(sic) about travel, free time, etc they seem to think the mechanics of dialysis far more important. Dialysis is a treatment which keeps us alive to live a life, not just to wait for death. – Patient receiving dialysis
"I prefer to be above ground, then below ground. So why not enjoy life whilst being above ground." Adam Martin
"Over the years, I have learned to worry less, control my emotions, and not fear death. I keep my mind active. I follow the advice of the philosopher-emperor Marcus Aurelius to 'love the hand that fate (has dealt me) and play it as (my) own'. Living well with CKD means to live the best life I can in the time I have available....Living well with CKD is the same as living well." – Tess Harris
"While CKD brings me some limitations, I can maximize the possibility to live well. I kept working when I was doing hemodialysis. After transplant, I could live: study, work, travel, marry, have children, and service the community." – Maggie Ng

***Personal communication; quotations are identified by name with permission**

erment, while feeling limited in life participation undermined their sense of empowerment.⁷

The WKDSC advocates for strengthened partnership with patients in the development, implementation, and evaluation of interventions for practice and policy settings, that enable patients to live well with kidney diseases. This needs to be supported by consistent, accessible, and meaningful communication. Meaningful involvement of patients and family members across the entire research process, from priority setting and planning the study through to dissemination and implementation, is now widely advocated.⁸ There have also been efforts, such as the 'Kidney Health Initiative', to involve patients in the development of drugs and devices to foster innovation.⁹

We urge for greater emphasis on a strengths-based approach (SBA) as outlined in [Table I](#), which encompasses strategies to support patient resilience, harness social connections, build patient awareness and

knowledge, facilitate access to support, and establish confidence and control in self-management. The SBA is in contrast to the medical model where chronic disease is traditionally focused on pathology, problems, and failures.¹⁰ Instead, the SBA acknowledges that each individual has strengths and abilities to overcome the problems and challenges faced, and requires collaboration and cultivation of the patient's hopes, aspirations, interests, and values. Efforts are needed to ensure that structural biases, discrimination, and disparities in the health care system also need to be identified, so all patients are given the opportunity to have a voice.

THE ROLE OF CARE-PARTNER (CP)

A CP is often an informal caregiver who is also a family member of the patient with CKD.¹¹ They may take on a wide range of responsibilities including coordinating care (including transportation to appointments), administration of treatment including medications, home dialysis assistance, and supporting dietary management. Caregivers of pa-

Table I: Suggested strategies for “living well with CKD” using a strengths-based approach.

Strengths-based approach	Suggested strategies
Build resilience	<ul style="list-style-type: none"> Identify or provide strategies and resources to manage stress and functioning when encountering challenges, adversity and trauma (e.g. commencement of dialysis)
Harness social connections	<ul style="list-style-type: none"> Facilitate connections with other patients to learn coping strategies and for support Support family members/caregivers
Build awareness and knowledge	<ul style="list-style-type: none"> Provide education (including practical advice) on diet and lifestyle modifications Understand, identify, and address the potential impacts of CKD (e.g. cognitive function). Encourage patients to ask questions. Encourage the use of knowledge to empower and prepare for the future.
Facilitate access to support	<ul style="list-style-type: none"> Refer to allied health care professionals (e.g. dietitian, social worker, mental health professionals, occupation therapists) Provide support that enables the patient to participate in important life activities e.g. work.
Establish confidence and control in self-management	<ul style="list-style-type: none"> Support informed and shared decision-making (including dialysis, kidney transplantation, conservative or non-dialytic care) Encourage patients to learn to “get in tune” with what works well for them and to voice any concerns, and work together to develop better management strategies to enable patients to feel better. Provide strategies to prevent or manage complications (e.g. infection) Support open communication regarding goals, concerns, and priorities

Abbreviations: CKD: chronic kidney disease (not receiving kidney replacement therapy)

tients with CKD have reported depression, fatigue, isolation, and also burnout. The role of the CP has increasingly become more important in CKD care given the heightened complexity in communicative and therapeutic options including the expansion of telemedicine under the COVID-19 pandemic and given the goal to achieve higher life expectancy with CKD.¹² The experience of caring for a partially incapacitated family member with progressive CKD can represent a substantial burden on the CP and may impact family dynamics. Not infrequently, the career goals and other occupational and leisure aspects of the life of the CP are affected because of CKD care partnership, leading to CP overload and burnout. Hence, the above-mentioned principles of life participation need to equally apply to CPs as well as all family members and friends involved in CKD care.

LIVING WITH KIDNEY DISEASE IN LOW-INCOME REGIONS

In low and lower-middle-income countries (LICs and LMICs) including in sub-Saharan Africa, South East Asia, and Latin America, patient’s ability to self-manage or cope with the chronic disease vary but may often be influenced by internal factors including spirituality, belief system, and religiosity, and external factors including appropriate knowledge of the disease, poverty, family support system, and one’s grit and social relations network. The support system comprising healthcare providers and caregivers plays a crucial role as most patients rely on them in making decisions, and for the necessary adjustments in their health behavior.¹³ In LIC regions, where there are often a relatively low number of physicians and even lower number of kidney care providers per population especially in rural areas, a stepwise approach can involve local and national stakeholders including both non-governmental organizations and government agencies by 1) extending kidney patient education in rural areas, 2) adapting telehealth technologies if

feasible to educate patients and train local community kidney care providers and 3) implementing effective retention strategies for rural kidney health providers including adapting career plans and competitive incentives.

Many patients in low resource settings present in very late stage needing to commence emergency dialysis.¹⁴ The very few fortunate ones to receive kidney transplantation may acquire an indescribable chance to normal life again, notwithstanding the high costs of immunosuppressive medications in some countries. For some patients and CPs in low-income regions, spirituality and religiosity may engender hope, when ill they are energized by the anticipation of restored health and spiritual wellbeing. For many patients, informing them of a diagnosis of kidney disease is a harrowing experience both for the patient (and caregivers) and the healthcare professional. Most patients present to kidney physicians (usually known as “renal physicians” in many of these countries) with trepidations and apprehension. It is rewarding therefore to see the patient’s anxiety dissipate after reassuring him or her of a diagnosis of simple kidney cysts, urinary tract infection, simple kidney stones, solitary kidneys, etc., that would not require extreme measures like kidney replacement therapy. Patients diagnosed with glomerulonephritis who have an appropriate characterization of their disease from kidney biopsies and histology; who receive appropriate therapies and achieve remission are relieved and are very grateful. Patients are glad to discontinue dialysis following resolution of AKI or acute on CKD.

Many CKD patients who have residual kidney function appreciate being maintained in a relatively healthy state with conservative measures, without dialysis. They experience renewed energy when their anemia is promptly corrected using erythropoiesis-stimulating agents. They are happy when

their peripheral oedema resolves with treatment. For those on maintenance hemodialysis who had woeful stories from emergency femoral cannulations, they appreciate the construction of good temporary or permanent vascular accesses. Patients remain grateful for waking from a uremic coma or recovering from recurrent seizures when they commence dialysis.

WORLD KIDNEY DAY 2021 ADVOCACY

World Kidney Day (WKD) 2021 theme on ‘Living Well with Kidney Disease’ is deliberately chosen to have the goals to redirect more focus on plans and actions towards achieving patient-centred wellness. “Kidney Health for Everyone, Everywhere” with emphasis on patient-centred wellness should be a policy imperative that can be successfully achieved if policy makers, nephrologists, health care professionals, patients, and care partners place this within the context of comprehensive care. The requirement of patient engagement is needed. WHO in 2016 put out an important document on patient empowerment (WHO 2016): ‘Patient engagement is increasingly recognized as an integral part of health care and a critical component of safe people-centred services. Engaged patients are better able to make informed decisions about their care options. In addition, resources may be better used if they are aligned with patients’ priorities and this is critical for the sustainability of health systems worldwide. Patient engagement may also promote mutual accountability and understanding between patients and health care providers. Informed patients are more likely to feel confident to report both positive and negative experiences and have increased concordance with mutually agreed care management plans. This not only improves health outcomes but also advances learning and improvement while reducing adverse events.’ In the ISN Community Film Event at World Con-

gress of Nephrology (WCN) 20 (ISN Community Film Event 2020), it is good to see a quote in the film from patients: "Tell me. I will forget; Show me. I will remember; Involve me. I will understand." ISN Global Kidney Policy Forum 2019 included a patient speaker Nicki Scholes-Robertson from New Zealand: 'Culturally appropriate and sensitive patient information and care are being undertaken in New Zealand to fight inequities in kidney health, especially in Maori and other disadvantaged communities.'

WKD 2021 would like to promote to the policy makers on increasing focus and resources on both drug and non-drug programmes in improving patient wellness. Examples include funding for erythropoiesis-stimulating agents and anti-pruritic agents for managing anemia and itchiness respectively, just to name but a few.^{15, 16} Home dialysis therapies have been consistently found to improve patient autonomy and flexibility, quality of life in a cost-effective manner, enhancing life participation. Promoting home dialysis therapies should tie in with appropriate 'assisted dialysis' programs to reduce patient and CP fatigue and burnout. Also, examples like self-management programmes, cognitive behavioural therapy, and group therapies for managing depression, anxiety, and insomnia should be promoted before resorting to medications.¹⁷ The principle of equity recognizes that different people with different levels of disadvantage require different approaches and resources to achieve equitable health outcomes. The kidney community should push for adapted care guidelines for vulnerable and disadvantaged populations. The involvement of primary care and general physicians especially in LICs and LMICs would be useful in improving the affordability and access to services through the public sector in helping the symptom management of CKD patients and improve their wellness. In the overall wellness program for kidney disease patients, the need for prevention should be

reiterated. Early detection with a prolonged course of wellness despite kidney disease, after an effective secondary prevention program, should be promoted.¹⁸ Prevention of CKD progression can be attempted by lifestyle and diet modifications such as a plant-dominant low protein diet and by means of effective pharmacotherapy including administration of sodium-glucose transport protein 2 (SGLT2) inhibitors.¹⁹ WKD 2021 continues to call for increased awareness of the importance of preventive measures throughout populations, professionals, and policy makers, applicable to both developed and developing countries.¹⁸

CONCLUSIONS

Effective strategies to empower patients and their CPs strive to pursue the overarching goal of minimizing the burden of CKD related symptoms in order to enhance patient satisfaction, health-related quality of life, and life participation. WKD 2021 theme on 'Living Well with Kidney Disease' is deliberately chosen to have the goals to redirect more focus on plans and actions towards achieving patient-centered wellness. Notwithstanding the COVID-19 pandemic that had overshadowed many activities in 2020 and beyond, the WKDSC has declared 2021 the year of "Living well with Kidney Disease" in an effort to increase education and awareness on the important goal of effective symptom management and patient empowerment. Whereas the WKD continues to emphasize the importance of effective measures to prevent kidney disease and its progression,¹⁸ patients with preexisting kidney disease and their CPs should feel supported to live well through concerted efforts by kidney care communities and other stakeholders throughout the world even during a world-shattering pandemic as COVID-19 that may drain many resources.²⁰ Living well with kidney disease is an uncompromisable goal of all kidney foundations, patient groups, and professional societies

alike, to which the International Society of Nephrology and the International Federation of Kidney Foundation World Kidney Alliance are committed at all times.

CONFLICT OF INTEREST

K.K.-Z. reports honoraria from Abbott, Abbvie, ACI Clinical, Akebia, Alexion, Amgen, Ardelyx, Astra-Zeneca, Aveo, BBraun, Cara Therapeutics, Chugai, Cytokinetics, Daiichi, DaVita, Fresenius, Genentech, Haymarket Media, Hospira, Kabi, Keryx, Kissei, Novartis, Pfizer, Regulus, Relypsa, Resverlogix, Dr Schaer, Sandoz, Sanofi, Shire, Vifor, UpToDate, and ZS-Pharma. P.K.T.L. reports personal fees from Fibrogen and Astra-Zeneca. G.S. reports personal fees from Multicare, Novartis, Sandoz, and Astra-Zeneca. V.L. reports nonfinancial support from Genesis Pharma.

PUBLICATION INFORMATION

This article is being published in *Kidney International* and reprinted concurrently in several journals. The articles cover identical concepts and wording, but vary in minor stylistic and spelling changes, detail, and length of manuscript in keeping with each journal's style. Any of these versions may be used in citing this article. Note that all authors contributed equally to the conception, preparation, and editing of the manuscript.

REFERENCES

- 1: Tong A, Manns B, Wang AYM, Hemmelgarn B, Wheeler DC, Gill J, Tugwell P, Pecoits-Filho R, Crowe S, Harris T, Van Biesen W, Winkelmayer WC, Levin A, Thompson A, Perkovic V, Ju A, Gutman T, Bernier-Jean A, Viecelli AK, O'Lone E, Shen J, Josephson MA, Cho Y, Johnson DW, Sautenet B, Tonelli M, Craig JC and Investigators SIW. [Implementing core outcomes in kidney disease: report of the Standardized Outcomes in Nephrology \(SONG\) implementation workshop](#). *Kidney Int.* 2018;94(6):1053-1068. doi: 10.1016/j.kint.2018.08.018. PubMed PMID: 30360959; PMCID: PMC6620755. [Accessed on 10 March 2021].
- 2: Carter SA, Gutman T, Logeman C, Cattran D, Lightstone L, Bagga A, Barbour SJ, Barratt J, Boletis J, Caster D, Coppo R, Fervenza FC, Floege J, Hladunewich M, Hogan JJ, Kitching AR, Lafayette RA, Malvar A, Radhakrishnan J, Rovin BH, Scholes-Robertson N, Trimarchi H, Zhang H, Azukaitis K, Cho Y, Viecelli AK, Dunn L, Harris D, Johnson DW, Kerr PG, Laboi P, Ryan J, Shen JI, Ruiz L, Wang AY, Lee AHK, Fung S, Tong MK, Teixeira-Pinto A, Wilkie M, Alexander SI, Craig JC, Tong A and Investigators S-G. [Identifying Outcomes Important to Patients with Glomerular Disease and Their Caregivers](#). *Clin J Am Soc Nephrol.* 2020;15(5):673-684. doi: 10.2215/CJN.13101019. PubMed PMID: 32354728; PMCID: PMC7269216. [Accessed on 10 March 2021].
- 3: Hanson CS, Craig JC, Logeman C, Sinha A, Dart A, Eddy AA, Guha C, Gipson DS, Bockenhauer D, Yap HK, Groothoff J, Zappitelli M, Webb NJA, Alexander SI, Furth SL, Samuel S, Neu A, Viecelli AK, Ju A, Sharma A, Au EH, Desmond H, Shen JI, Manera KE, Azukaitis K, Dunn L, Carter SA, Gutman T, Cho Y, Walker A, Francis A, Sanchez-Kazi C, Kausman J, Pearl M, Benador N, Sahney S, Tong A and investigators SO-Kcw. [Establishing core outcome domains in pediatric kidney disease: report of the Standardized Outcomes in Nephrology-Children and Adolescents \(SONG-KIDS\) consensus workshops](#). *Kidney Int.* 2020. doi: 10.1016/j.kint.2020.05.054. PubMed PMID: 32628942.
- 4: Gonzalez AM, Gutman T, Lopez-Vargas P, Anumudu S, Arce CM, Craig JC, Dunn L, Eckardt KU, Harris T, Levey AS, Lightstone L, Scholes-Robertson N, Shen JI, Teixeira-Pinto A, Wheeler DC, White D, Wilkie M, Jadoul M, Winkelmayer WC and Tong A. [Patient and caregiver priorities for outcomes in CKD: a multinational nominal group technique study](#). *Am J Kid Dis.* 2020:doi: 10.1053/j.ajkd.2020.03.022. Online ahead of print. doi. PubMed PMID. [Accessed on 10 March 2021].
- 5: WHO. [Towards a common language for functioning, disability and health](#). 2002;WHO/EIP/GPE/CAS/01.3. [Accessed on 10 March 2021].
- 6: WHO. [Health Promotion Glossary](#). 1998;WHO/HPR/HEP/98.1. [Accessed on 10 March 2021].
- 7: Baumgart A, Manera KE, Johnson DW, Craig

- JC, Shen JI, Ruiz L, Wang AY, Yip T, Fung SKS, Tong M, Lee A, Cho Y, Viecelli AK, Sautenet B, Teixeira-Pinto A, Brown EA, Brunier G, Dong J, Scholes-Robertson N, Dunning T, Mehrotra R, Naicker S, Pecoits-Filho R, Perl J, Wilkie M and Tong A. Meaning of empowerment in peritoneal dialysis: focus groups with patients and caregivers. *Nephrol Dial Transplant.* 2020. doi: 10.1093/ndt/gfaa127. PubMed PMID: 32712672.
- 8: PCORI. [The Value of Engagement](#). 2018. [Accessed 1st September 2020].
- 9: Bonventre JV, Hurst FP, West M, Wu I, Roy-Chaudhury P and Sheldon M. [A Technology Roadmap for Innovative Approaches to Kidney Replacement Therapies: A Catalyst for Change](#). *Clin J Am Soc Nephrol.* 2019;14(10):1539-1547. doi: 10.2215/CJN.02570319. PubMed PMID: 31562182; PMID: PMC6777588. [Accessed on 10 March 2021].
- 10: Ibrahim N, Michail M and Callaghan P. [The strengths based approach as a service delivery model for severe mental illness: a meta-analysis of clinical trials](#). *BMC Psychiatry.* 2014;14:243. doi: 10.1186/s12888-014-0243-6. PubMed PMID: 25189400; PMID: PMC4154523. [Accessed on 10 March 2021].
- 11: Parham R, Jacyna N, Hothi D, Marks SD, Holttum S and Camic P. [Development of a measure of caregiver burden in paediatric chronic kidney disease: The Paediatric Renal Caregiver Burden Scale](#). *Journal of health psychology.* 2014. doi: 10.1177/1359105314524971. PubMed PMID: 24648321. [Accessed on 10 March 2021].
- 12: Subramanian L, Kirk R, Cuttitta T, Bryant N, Fox K, McCall M, Perry E, Swartz J, Restovic Y, Jeter A, Bernardo A, Robinson B, Perl J, Pisoni R and Perlman RL. [Remote Management for Peritoneal Dialysis: A Qualitative Study of Patient, Care Partner, and Clinician Perceptions and Priorities in the United States and the United Kingdom](#). *Kidney Med.* 2019;1(6):354-365. doi: 10.1016/j.xkme.2019.07.014. PubMed PMID: 32734216; PMID: PMC7380395. [Accessed on 10 March 2021].
- 13: Angwenyi V, Aantjes C, Kajumi M, De Man J, Criel B and Bunders-Aelen J. [Patients experiences of self-management and strategies for dealing with chronic conditions in rural Malawi](#). *PLoS One.* 2018;13(7):e0199977. doi: 10.1371/journal.pone.0199977. PubMed PMID: 29965990; PMID: PMC6028088. [Accessed on 10 March 2021].
- 14: Ulasi, II and Ijoma CK. [The enormity of chronic kidney disease in Nigeria: the situation in a teaching hospital in South-East Nigeria](#). *J Trop Med.* 2010;2010:501957. doi: 10.1155/2010/501957. PubMed PMID: 20613945; PMID: PMC2896838. [Accessed on 10 March 2021].
- 15: Spinowitz B, Pecoits-Filho R, Winkelmayr WC, Pergola PE, Rochette S, Thompson-Leduc P, Lefebvre P, Shafai G, Bozas A, Sanon M and Krassa HB. [Economic and quality of life burden of anemia on patients with CKD on dialysis: a systematic review](#). *J Med Econ.* 2019;22(6):593-604. doi: 10.1080/13696998.2019.1588738. PubMed PMID: 30813807. [Accessed on 10 March 2021].
- 16: Sukul N, Speyer E, Tu C, Bieber BA, Li Y, Lopes AA, Asahi K, Mariani L, Laville M, Rayner HC, Stengel B, Robinson BM, Pisoni RL, Ckdopps and investigators C-R. [Pruritus and Patient Reported Outcomes in Non-Dialysis CKD](#). *Clin J Am Soc Nephrol.* 2019;14(5):673-681. doi: 10.2215/CJN.09600818. PubMed PMID: 30975656; PMID: PMC6500934. [Accessed on 10 March 2021].
- 17: Gregg LP and Hedayati SS. Pharmacologic and psychological interventions for depression treatment in patients with kidney disease. *Curr Opin Nephrol Hypertens.* 2020;29(5):457-464. doi: 10.1097/MNH.0000000000000629. PubMed PMID: 32701597.
- 18: Li PK, Garcia-Garcia G, Lui SF, Andreoli S, Fung WW, Hradsky A, Kumaraswami L, Liakopoulos V, Rakhimova Z, Saadi G, Strani L, Ulasi I, Kalantar-Zadeh K and World Kidney Day Steering C. [Kidney health for everyone everywhere-from prevention to detection and equitable access to care](#). *Brunei Int Med J.* 2020;16:60-72. [Accessed on 10 March 2021].
- 19: Kalantar-Zadeh K and Li PK. Strategies to prevent kidney disease and its progression. *Nat Rev Nephrol.* 2020;16(3):129-130. doi: 10.1038/s41581-020-0253-1. PubMed PMID: 32005966.
- 20: Kalantar-Zadeh K, Wightman A and Liao S. [Ensuring Choice for People with Kidney Failure - Dialysis, Supportive Care, and Hope](#). *N Engl J Med.* 2020;383(2):99-101. doi: 10.1056/NEJMp2001794. PubMed PMID: 32640129. [Accessed on 10 March 2021].